About CJC-1295 NO DAC
CJC-1295 NO DAC is the non-conjugated form of the CJC-1295 series, a 29-amino-acid growth hormone-releasing hormone analogue sometimes referred to as modified GRF(1–29). Engineered substitutions in the native sequence protect against rapid enzymatic breakdown, giving the peptide improved stability relative to native GRF while retaining a comparatively short duration of action. Researchers select it for studies of acute GHRH-receptor signaling, growth hormone release kinetics, and dose-response mapping in pituitary cell assays and small-animal models. It is also used as a control alongside the DAC-conjugated variant to compare the pharmacodynamic consequences of albumin conjugation. Quality considerations include deamidation of asparagine residues during synthesis or storage, oxidation of methionine, and truncation products that alter receptor activation. Shandong Shengyuan verifies every batch by RP-HPLC at 99.7% purity or higher, high-resolution LC-MS, and peptide-content quantification, shipping each lot lyophilized with complete batch documentation. For research use only; not for human or veterinary use.
Research Applications
- Acute GHRH signaling assays
- GH release kinetics studies
- Dose-response mapping
- Modified GRF stability research
- Pituitary pharmacology
Quality & Documentation
Every batch of CJC-1295 NO DAC is manufactured under our documented quality system and released with a Certificate of Analysis covering HPLC purity, mass spectrometry identity, peptide content, water content, and endotoxin. The batch code on your vial can be verified online in the COA lookup section of this site.
Tesamorelin
Sermorelin Acetate
Ipamorelin